Comparison
Bromantane vs Hexarelin
Side-by-side of Bromantane and Hexarelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Bromantane
Bromantane, the Russian nootropic sold as Ladasten (ADK-709), acts on dopamine to cut fatigue and anxiety without classical stimulant rebound.
Hexarelin
Hexarelin peptide is a ghrelin-receptor hexapeptide. Largest acute GH pulse in the GHRP class, highest cortisol and prolactin lift, CD36 cardioprotective sign.
Effects at a glance
Bromantane
- •Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
- •Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
- •Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
- •Long half-life of around 11 hours supports once-daily morning dosing
- •WADA-banned since 1996; relevant for tested athletes
- •Western evidence base is thin; most published trials are Russian-language and not independently replicated
Hexarelin
- •Synthetic hexapeptide GHS-R1a agonist; produces the largest acute GH pulse of the synthetic GHRP class
- •Independent CD36 signaling produces cardioprotective effects in rodent ischemia models, GH-independent
- •Pronounced tachyphylaxis: GH response attenuates over 2 to 4 weeks of daily dosing
- •More cortisol and prolactin elevation than GHRP-2 or ipamorelin
- •Anecdotal protocols use 100 to 200 mcg subcutaneously 1 to 2 times daily for 2 to 4 week pulses
- •Banned by WADA under S2; advanced through phase 2 trials but never reached registration
Side-by-side
| Attribute | Bromantane | Hexarelin |
|---|---|---|
| Category | nootropic | peptide |
| Also known as | Ladasten, ADK-709, N-(4-bromophenyl)adamantan-2-amine | Examorelin, EP-23905, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 |
| Half-life (hr) ↗ | 11 | 1 |
| Typical dose (mg) ↗ | 75 | 0.1 |
| Dosing frequency | daily, morning | 1-2x daily |
| Routes | oral | subcutaneous, intranasal, intravenous |
| Onset (hr) | 3 | 0.25 |
| Peak (hr) | 168 | 0.5 |
| Molecular weight | 280.21 | 887.04 |
| Molecular formula | C16H20BrN | C47H58N12O6 |
| Mechanism | Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus. | Hexapeptide agonist of GHS-R1a producing acute GH release with cortisol and prolactin co-elevation. Independent CD36 binding produces GH-independent cardioprotective signaling in preclinical models. |
| Legal status | Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK | Not FDA approved; advanced through phase 2 trials in EU but never registered; research-use-only grey market; banned by WADA |
| WADA status | banned | banned |
| DEA / Rx | Not scheduled in the US | Not scheduled (research chemical) |
| Pregnancy | Not recommended | Insufficient data; not recommended |
| CAS | 87913-26-6 | 140703-51-1 |
| PubChem CID | 9576456 | 3037387 |
| Wikidata | Q4093816 | Q5743550 |
Safety profile
Bromantane
Common side effects
- mild GI upset
- headache
- skin rash
- occasional insomnia at higher doses
Contraindications
- pregnancy
- lactation
- severe hepatic impairment
- severe renal impairment
- pediatric use
Interactions
- MAOIs: theoretical additive dopaminergic and serotonergic activity(major)
- levodopa and dopamine agonists: additive dopaminergic activity(moderate)
- SSRIs and other serotonergic drugs: theoretical serotonergic additivity(moderate)
- classical stimulants: theoretical additive activity, undocumented(moderate)
Hexarelin
Common side effects
- water retention
- vivid dreams
- head pressure or flushing
- transient lethargy
- tingling at injection site
- moderate hunger
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
- prolactin-sensitive states
Interactions
- CJC-1295: synergistic GH release; accelerates tachyphylaxis if used continuously(minor)
- sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: amplify cortisol load; blunt GH response(moderate)
Which Should You Take?
Bromantane comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-C outcome catalogued. Hexarelin is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Bromantane.
- → If your priority is fatigue resistance, pick Bromantane.
- → If your priority is growth-hormone axis, pick Hexarelin.
- → If your priority is post-training recovery, pick Hexarelin.
Edge case: If you cannot self-administer injections, Bromantane is the only oral option in this pair.
Default choice: Bromantane. Wider use case, and broader goal coverage. Reach for Hexarelin only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Bromantane and Hexarelin?
Bromantane and Hexarelin differ in category (nootropic vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Bromantane or Hexarelin?
Bromantane half-life is 11 hours; Hexarelin half-life is 1 hours.
Can you stack Bromantane with Hexarelin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper